CHILDRENS CANCER GROUP

儿童癌症组

• 批准号: 2009150
• 负责人: Leonard Stanley Sender
• 金额: $ 5.45万
• 依托单位: CHILDREN'S HOSPITAL OF ORANGE COUNTY
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-04-25 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2009150
• 关键词: 6 thiopurine; Burkitt's lymphoma; Ewing's tumor; Hodgkin's disease; Wilms' tumor; XomaZyme; acivicin; acute leukemia; acute lymphocytic leukemia; acute myelogenous leukemia; adolescence (12-20); antineoplastics; asparaginase; astrocytoma; biological response modifiers; bone marrow transplantation; brain neoplasms; cancer registry /resource; cancer risk; central nervous system neoplasms; child (0-11); chronic myelogenous leukemia; cis platinum compound; clinical research; clinical trial phase I; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cyclosporines; cytokine; cytosine arabinoside; daunorubicin; deferoxamine; deoxycoformycin; doxorubicin; drug screening /evaluation; enalapril; ependymoma; etoposide; fazarabine; fluorouracil; germ cell neoplasms; glioma; hematopoiesis; hematopoietic stem cells; hepatoblastoma; hepatocellular carcinoma; human genetic material tag; human immunodeficiency virus 1; human subject; human therapy evaluation; human tissue; ifosfamide; interferons; interleukin 12; interleukin 15; interleukin 2; medulloblastoma; melphalan; metastasis; methotrexate; mitoxantrone; molecular oncology; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer surgery; neuroblastoma; nonHodgkin's lymphoma; osteosarcoma; paclitaxel; pediatric pharmacology; podophyllin; prednisone; retinoate; rhabdomyosarcoma; tissue resource /registry; topotecan; trimetrexate; vincristine

Children's Hospital of Orange County (CHOC) was only recently approved as a full member institution (April 1993) in Childrens Cancer Group (CCG). Despite being a full member for only eighteen months, CHOC investigators have contributed significantly to the development of new therapeutic protocols, the establishment of two reference laboratories, and have provided significant scientific and administrative leadership within CCG. CHOC currently registers all eligible patients on to CCG protocols and is an approved CCG phase I and Bone Marrow Transplant institution. The long- term objective of this proposal is to further the improvement in the prevention, diagnosis, and treatment of childhood cancer through participation in CCG. The specific aims of this proposal include: l) providing leadership in several strategy groups, discipline committees, and study committees; 2) expanding the reference laboratories for lymphoma studies and hematopoiesis/cytokine translational research; 3) providing leadership and implementation of group phase I trials; and 4) developing pilot studies that can be translated and implemented into groupwide studies. There are presently 7 investigators at CHOC participating in 32 committee appointments. The recruitment of additional CHOC investigators will provide additional scientific and administrative CCG leadership at the level of the strategy group, study chair, study vice chair, and within scientific and discipline committees. The CHOC Hematopoisis/Cytokine Laboratory will continue to investigate stem cell regulation and cytokine receptor modulation, develop methods for ex vivo isolation and expansion of stem cells (CD34), and optimize the mobilization of peripheral stem cells for repetitive submyeloablative therapy. The Lymphoma Reference Laboratory will continue to investigate the oncogenesis of childhood lymphomas and develop alternative treatment strategies, including antisense gene therapy for Burkitt's lymphoma. Pilot phase I trials in biotherapy, immunotherapy, and hematopoiesis, including lL-2 and activated leukocytes, IL-12 + IL-15 immunotherapy, auto-graft-vs-host tumor induction, and the use of new cytokines, including thrombopoietin, will be explored at CHOC and will potentially lead to groupwide studies. In summary, CHOC will continue to provide leadership for pilot studies through CCG, participate in all open CCG phase I, II, III, and bone marrow transplant studies, develop protocols for determining the long-term effects of chemo-radiotherapy and immunotherapy, and conduct specific biological investigations in the areas of experimental hematopoiesis and childhood lymphoma.

奥兰治县儿童医院（CHOC）直到最近才被批准 儿童癌症组（CCG）的完整会员机构（1993年4月）。 尽管只有十八个月的正式会员，但CHOC调查人员还是 为新治疗的发展做出了重大贡献 协议，建立两个参考实验室，并具有 在CCG内提供了重要的科学和行政领导。 CHOC目前将所有合格的患者注册到CCG方案中，IS 获得批准的CCG I期和骨髓移植机构。长期 该提议的术语目标是进一步改善 预防，诊断和治疗儿童癌症 参加CCG。该提案的具体目的包括：l） 在多个战略团体，纪律委员会中提供领导地位， 和学习委员会； 2）扩展参考实验室 淋巴瘤研究和造血/细胞因子转化研究； 3） 提供I阶段试验的领导和实施；和4） 开发可以翻译和实施到的试点研究 整个研究。目前有7名调查员 参加32个委员会任命。招募额外 巧克力调查人员将提供其他科学和行政 CCG在战略小组，学习主席，研究水平的领导 副主席以及科学和纪律委员会内。 巧克力 造血/细胞因子实验室将继续研究干细胞 调节和细胞因子受体调制，开发离体的方法 干细胞的隔离和扩展（CD34），并优化 动员周围干细胞重复的子源性 治疗。淋巴瘤参考实验室将继续调查 儿童淋巴瘤的肿瘤发生并发展替代治疗 策略，包括伯基特淋巴瘤的反义基因治疗。 试点I期生物疗法，免疫疗法和造血试验， 包括LL-2和活化的白细胞，IL-12 + IL-15免疫疗法， 自动移植-VS-host肿瘤诱导和新细胞因子的使用， 包括血栓蛋白在内，将在CHOC探索，并有可能 导致整个研究。总而言之，CHOC将继续提供 通过CCG进行试点研究的领导，参加所有开放CCG 第一阶段，II，III和骨髓移植研究，制定方案 用于确定化学疗法的长期影响和 免疫疗法，并在 实验性造血和儿童淋巴瘤的区域。